Trial
NCT02530502
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Northwestern University
Collaborators
Merck Sharp & Dohme LLC; National Cancer Institute (NCI)
Condition
Adult Glioblastoma
Intervention
Laboratory Biomarker Analysis
Why stopped
The protocol was amendment to be stopped after phase I (phase 2 removed from protocol)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-18